2 results
Approved WMOWill not start
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
Approved WMOCompleted
Our research objective is to test the hypothesis that patient outcomes can be improved through the development of instrumented retractors for cardiothoracic surgery. By monitoring and controlling retraction forces, damage to the chest wall and…